Kazia Therapeutics Limited

NasdaqCM KZIA

Kazia Therapeutics Limited Free Cash Flow Yield on January 15, 2025

Kazia Therapeutics Limited Free Cash Flow Yield is NA on January 15, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Kazia Therapeutics Limited 52-week high Free Cash Flow Yield is NA on None, which is NA below the current Free Cash Flow Yield.
Kazia Therapeutics Limited 52-week low Free Cash Flow Yield is NA on None, which is NA below the current Free Cash Flow Yield.
Kazia Therapeutics Limited average Free Cash Flow Yield for the last 52 weeks is NA.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: KZIA

Kazia Therapeutics Limited

CEO	Dr. John Edwin Friend II, M.D.
IPO Date	Jan. 6, 1999
Location	Australia
Headquarters	Three International Towers
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key trends

Past 5 years